NETSPOT KIT

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

OXODOTREOTIDE

から入手可能:

NOVARTIS PHARMACEUTICALS CANADA INC

ATCコード:

V09I

INN（国際名）:

TUMOUR DETECTION

投薬量:

40MCG

医薬品形態:

KIT

構図:

OXODOTREOTIDE 40MCG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

15G/50G

処方タイプ:

Schedule C

治療領域:

ROENTGENOGRAPHY

製品概要:

Active ingredient group (AIG) number: 0161570001; AHFS:

認証ステータス:

APPROVED

承認日:

2019-07-03

製品の特徴

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
NETSPOT®
40 microgram kit for the preparation of gallium (
68
Ga) oxodotreotide for injection
Diagnostic Radiopharmaceutical Kit
Novartis Pharmaceuticals Canada Inc.
700 Saint-Hubert St., Suite 100
Montreal, Quebec
H2Y 0C1
Date of Initial Authorization:
Jul 03, 2019
Date of Revision:
Feb 28, 2024
Submission Control Number: 282568
NETSPOT is a registered trademark
_NETSPOT® (kit for the preparation of gallium (_
_68_
_Ga) oxodotreotide injection) _
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
4 Dosage and Administration, 4.4 Administration
06/2021
4 Dosage and Administration, 4.7 Instructions for Preparation and
Use
06/2021
4 Dosage and Administration, 4.8 Radiation Dosimetry
06/2021
7 Warnings and Precautions
06/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................4
1.2
Geriatrics
..............................................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
4
4
DOSAGE AND ADMINISTRATION
.............................................................................................
4
4.1
Dosing Considerations
...........................................................